Cargando…
Genomics of PDGFR-rearranged hypereosinophilic syndrome
Autores principales: | Rheinbay, Esther, Qi, Meifang, Bouyssou, Juliette M., Oler, Andrew J., Thumm, Lauren, Makiya, Michelle, Maric, Irina, Klion, Amy D., Lane, Andrew A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250933/ https://www.ncbi.nlm.nih.gov/pubmed/36652685 http://dx.doi.org/10.1182/bloodadvances.2022009061 |
Ejemplares similares
-
Clinical and Biological Markers in Hypereosinophilic Syndromes
por: Khoury, Paneez, et al.
Publicado: (2017) -
COVID-19 infection in hypereosinophilic syndrome: A survey-based analysis
por: Espinoza, David F., et al.
Publicado: (2022) -
Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2
por: Romagnoli, Simone, et al.
Publicado: (2021) -
Renal thrombotic microangiopathy and FIP1L1/PDGFRα-associated myeloproliferative variant of hypereosinophilic syndrome
por: Langlois, Anne Lyse, et al.
Publicado: (2013) -
Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial
por: Roufosse, Florence, et al.
Publicado: (2020)